In a study of KRAS mutated CRC, which is associated with resistance to anti-EGFR (epidermal growth factor receptor) therapies, Duo et al. showed circRNA expression was more likely to be downregulated in KRAS-mutant colon cancer cell lines compared to wild-type (Dou et al., 2016). This evidence concerns the gene KRAS and colorectal carcinoma.